
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.06 | 1.82370820669 | 3.29 | 3.49 | 3 | 20243 | 3.33525436 | CS |
4 | 0.45 | 15.5172413793 | 2.9 | 3.49 | 2.665 | 85580 | 2.97220303 | CS |
12 | -0.795 | -19.17973462 | 4.145 | 7.3 | 2.01 | 290678 | 5.55765486 | CS |
26 | -1.79 | -34.8249027237 | 5.14 | 7.3 | 2.01 | 147340 | 5.51456194 | CS |
52 | -9.92 | -74.7550866616 | 13.27 | 16.0675 | 2.01 | 139796 | 8.79694874 | CS |
156 | -52.65 | -94.0178571429 | 56 | 92.5 | 2.01 | 191389 | 22.39539747 | CS |
260 | -390.9 | -99.1502853519 | 394.25 | 449.75 | 2.01 | 219079 | 70.58956861 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.